During Epilepsy Awareness Month, as part of our commitment to providing solutions that positively impact the lives of patients with neurological conditions, we enthusiastically announce a new initiative with Medisafe – the leading integrated medication management platform, personalized to engage patients and deliver outcomes.  

Michele has lived with tonic-clonic seizures since the age of 28 when she experienced her first seizure while swimming in a pool. This Epilepsy Awareness Month, read about her journey to seizure freedom. 

33 Winners of the UCB Family Epilepsy Scholarship demonstrate UCB’s commitment to patients.

The COVID-19 pandemic is changing the way we view health care. It

has brought to the forefront of public conversation sobering truths about how social and racial disparities impact the health outcomes of underserved populations in the United States. Often, we attribute an individual’s health solely to the quality of health care they receive when in fact, a host of factors that occur outside clinical walls can play an even greater role in a person’s well-being. Social Determinants of Health (SDH) are the conditions in which people are born, grow, live, work and age, such as socioeconomic factors, housing, physical environment, education, employment, social support and access to health care. SDH can affect a wide range of health outcomes and quality of life, especially for individuals battling chronic illnesses like epilepsy.

Six poster presentations highlight clinical data on NAYZILAM^® (midazolam) nasal spray CIV and BRIVIACT^® (brivaracetam) CV in addition to epilepsy-related health economics outcomes research

Atlanta, Ga., June 24, 2020: UCB today announced six posters selected for presentation at the 72nd American Academy of Neurology (AAN) annual meeting, available online via the 2020 AAN Science Highlights virtual platform, which replaced the in-person event previously cancelled due to the COVID-19 pandemic. The abstracts were also published in the online supplement to Neurology.

• Underlines UCB’s leadership in epilepsy by adding Staccato^® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure

As UCB attends the 2019 American Epilepsy Society meeting in Baltimore, Maryland this week, Mike Davis, Head of Neurology in the U.S., talks about the long way to go in managing epilepsy, and how UCB is committed to closing this gap by bringing new solutions to market. Read the article on LinkedIn.

At UCB, we keep patients at the center - inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. We have a rich heritage in epilepsy, and today, we’re shining a spotlight on seizure clusters, which can affect people with uncontrolled epilepsy, to help spread awareness. Check out the full infographic below.

At UCB, we keep patients at the center - inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. We have a rich heritage in epilepsy, and today, we’re shining a spotlight on seizure clusters, which can affect people with uncontrolled epilepsy, to help spread awareness.